AstraZenecaIt was never anticipated that the failure of the late-stage trial against Mr Wainua would have a significant financial impact on the company.
Most analysts estimate that this trial failure wiped just 2% to 4% from the rating model. But the stock price fell by about twice that amount in a single session, suggesting the market reaction reflected more than the loss of one drug aimed at treating a rare heart disease.
This disconnect shifted attention away from Wainua itself and toward something more difficult to measure. The question is whether the valuation premium investors have long assigned to one of Europe’s most prized drug pipelines is justified.
AstraZeneca has long enjoyed one of the richest valuations of any major European drug company, based on its management’s consistently successful late-stage clinical trials across oncology, rare diseases and specialty medicines, and its ability to replenish its portfolio with new blockbuster drugs.
Under CEO Pascal Soriot’s 14-year reign, AstraZeneca has built a reputation as a pharmaceutical giant that rarely releases negative trial results.
Wainua itself was not expected to become one of AstraZeneca’s biggest products. Rather, the surprise was that a program that many investors saw as having a high chance of success failed.
Most analysts said the disappointment didn’t hurt AstraZeneca’s long-term growth story, but it may have raised the bar to prove it.
The issue goes beyond the additional revenue Wainua would have added to AstraZeneca’s sales and hurts the company’s credibility, Jefferies analysts said in a note to clients on Thursday.
“This was meant to be a slam dunk, so the complete failure was surprising.”
Something bigger than one drug
The economic impact of Wainua’s failure as a treatment for ATTR cardiomyopathy, a rare and life-threatening heart disease, appears to be relatively small.
Citi estimates the net present value impact to be approximately 3%. Jefferies expects it to be around 2%, and Leerink Partners’ price target cut suggests similarly limited damage. Bank of America described the impact on sales as “mid-single digits,” while Morningstar said the decline in Wainua’s sales estimates would not materially change its rating for the company.
Those expectations contrast with the market’s reaction, with the stock falling 6.2% in Thursday trading, its worst day in more than two years, and falling another 3% on Friday.
An AstraZeneca spokeswoman declined further comment on the stock price reaction.
Investors may be reevaluating their confidence in AstraZeneca’s broader pipeline and execution, rather than simply excluding some of Wainua’s sales from the model.
Dan Coatsworth, head of markets at AJ Bell, said AstraZeneca has had far more hits than hits recently, raising expectations for success.
“AstraZeneca has a bold plan to reach $80 billion in sales by 2030, and investors will now ask whether this goal is credible,” Coatsworth said in emailed comments.
Jeffries said the trial failure does not threaten management’s 2030 goals and that Citi remains hopeful the company can exceed those goals.
Leerink noted that after discussions with management, firing Wainua for ATTR cardiomyopathy would reduce the headroom above the company’s stated consensus of approximately $82.7 billion to approximately $80.8 billion, which reflects Wainua’s 2030 revenue of $1.9 billion.
Morningstar maintained its fair value estimate and said the setback “does not change our view of the company’s late-stage drug development capabilities,” while noting that AstraZeneca’s oncology franchise, rare disease business, and extensive pipeline remain intact.
Both Goldman Sachs and Bank of America stressed that investors had not seriously considered the possibility of a failure. of alnylam A rival drug Amvuttra that works similarly.
Is the margin of error shrinking?
The study failure comes at a critical time for AstraZeneca.
Some of the company’s biggest pipeline catalysts, including the AVANZAR trial in lung cancer, SERENA-4 in breast cancer, and cliramitug in ATTR cardiomyopathy, are expected to report data in the coming months, meaning investor attention is now focused on a few high-profile data.
AstraZeneca’s London-listed shares over the past 12 months.
“All eyes are on AVANZAR,” Jeffries wrote, noting that AVANZAR is the next major catalyst likely to determine sentiment. An announcement is expected in July or August.
Leerink suggested the setback will put more emphasis on remaining “binary events” expected later this year.
Most analysts continue to recommend the stock as a buy. Citi reiterated AstraZeneca as a top contender for the European drug market, Bank of America reiterated its buy rating and Jefferies said investors should “buy the bullshit.”
